Breast Tumor Articles & Analysis
32 news found
This collaboration, facilitated by Aspire Financial, LLC., will provide SEngine’s cutting-edge diagnostic PARIS Test to first responders and other patients at Vincere Cancer Center. A patient’s tumor biopsy or surgical resection will be generated at Vincere and then sent to SEngine’s laboratory in Seattle, where up to 44 drugs from a library of over 240 options ...
SEngine's CLIA certified PARIS® Test generates actionable drug sensitivity reports for patients and is applicable to all solid tumors including colon, breast, lung, ovarian and pancreatic cancer. ...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. ...
“We are eager to bring XMT-2056 and its unique mechanism of action into the clinic mid-year to investigate its safety, tolerability and anti-tumor activity in gastric and other cancers.” XMT-2056 is designed to offer a differentiated and complementary therapeutic approach to existing and emerging solid tumor treatments. ...
The study, which enrolled 194 eligible patients, is the largest controlled multicenter clinical trial ever performed in the U.S. for LN2 based cryoablation of small, low-risk, early-stage malignant breast tumors as an alternative to surgery Dr. Tomkovich commented, “The inclusion of the ICE3 clinical trial interim results as part of the scientific program ...
PathPresenter, a pioneer in the development of digital pathology software, and 4D Path Inc., developer of a pan-cancer diagnostic and precision oncology platform enabling AI-based biomarker typing and prognostication from H&E images, are announcing today a global partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter’s new Clinical Workflow ...
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for ...
Approximately 300 patients undergoing breast conservation surgery across eight U.S. clinical sites are expected to participate in the pivotal trial, with study completion anticipated by the end of 2022. ...
This basket trial will include detection of circulating tumor DNA (ctDNA) across various solid tumors, including lung cancer, breast cancer, sarcoma and gastrointestinal (GI) cancers. ...
AV-203 has demonstrated preclinical activity in a number of different tumor models, including breast, head and neck, lung, ovarian and pancreatic cancers. ...
It is expected to improve the safety of and combat the resistance to currently approved CDK4/6 inhibitors that are given in combination with endocrine-based therapy for treatment of pre/perimenopausal or postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. In cell model ...
Approximately one-third of patients diagnosed with hormone receptor (HR)-positive, HER2- negative early breast cancer have a tumor that has spread to their lymph nodes. The vast majority of these patients currently receive chemotherapyiii even though approximately 85% of them have Recurrence Score results 0 to 25.iv In addition, approximately two out of three ...
Approximately one-third of patients diagnosed with hormone receptor (HR)-positive, HER2- negative early breast cancer have a tumor that has spread to their lymph nodes. The vast majority of these patients currently receive chemotherapyii even though approximately 85% of them have Recurrence Score results of 0 to 25.iii In addition, approximately two out of three ...
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. ...
Live tumor models from a biopsy or surgical resection of a patient’s primary or metastatic brain tumor will be generated at the Dana-Farber Center for Patient Derived Models (CPDM) using methods they have established for maximizing the viability of brain tumor cells. ...
The independent study conducted at the St. Marianna University Breast & Imaging Center, Kawasaki City, Japan enrolled eight female patients, 53 – 72 years-old mean age 62 years, diagnosed with invasive ductal carcinoma (IDC) tumors. Percutaneous ultrasound-guided cryoablation of the breast tumor was performed using ...
(NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that the first peer reviewed article “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral ...
The Test pre-screens a broad panel of cancer drugs on live patient-derived tumor cells with a battery of oncology drugs selected from a menu of targeted and less-toxic medications. ...
“Our preclinical data demonstrate that LAVA-051 targets CD1d-expressing tumors by activating both Vγ9Vδ2 T cells and type 1 NKT cells, leading to robust antitumor activity. ...
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session ...